We studied the effects of epalrestat, a speci®c inhibitor of aldose reductase, on renal sorbitol accumulation and the resulting urinary enzyme excretion in hyperglycaemic rats.
INTRODUCTION
Urinary enzyme excretion is increased in the earliest stages of diabetic nephropathy. 1, 2 We have previously reported that urinary enzyme excretion is increased in diabetic patients with clinically normal renal function (serum creatinine: men 4115 mmol/L; women 497 mmol/L) and normal urinary albumin excretion (522 mg/ day). 3, 4 In addition, previous studies on Wistar rats in our laboratory demonstrated that glucose loading increases urinary excretion of proximal tubule-derived enzymes such as N-acetyl-b-D-glucosaminidase (EC 3.2.1.30, NAG), alanine aminopeptidase (EC 3.4.11.2, AAP), g-glutamyltranspeptidase (EC 2.3.2.2, GGT) and dipeptidyl aminopeptidaseIV (EC 3.4.14.5, DAPIV). 5, 6 At the same time, renal cortical sorbitol concentration was also elevated. 6 These studies suggested that accumulation of intracellular sorbitol may lead to proximal tubular cell dysfunction manifested as abnormal enzymuria.
There is overwhelming evidence that accumulation of intracellular sorbitol produced by the activated polyol pathway leads to cell damage, resulting in late diabetic complications such as neuropathy and retinopathy. 7±10 In the polyol pathway, aldose reductase (EC 1.1.1.21) is the rate-limiting key enzyme and sorbitol is produced from D-glucose in an NADPH-dependent reduction reaction catalysed by this enzyme. 11 However, there have been very few studies of the involvement of the polyol pathway in nephropathy.
To determine whether the polyol pathway is associated with the development of diabetic nephropathy, we examined the effects of a speci®c aldose reductase inhibitor, epalrestat, on urinary enzyme excretion, the most salient index of renal function in hyperglycaemia.
MATERIALS AND METHODS

Animals
The procedures used in this study were approved by Kitasato University Institutional Animal Care and Use Committee. Experiments were carried out on male Wistar rats (Japan SLC Co, Hamamatsu, Japan) weighing between 250 and 350 g. In the epalrestat (5-[(1Z, 2E)-2methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid; Ono Pharmaceutical, Osaka, Japan) treatment group, the drug was administered at a dose of 50 mg/kg body weight/ day in standard laboratory chow (CE-2, Clea Japan, Tokyo, Japan) for 2 weeks before the acute infusion study. Other rats were allowed free access to standard chow and tap water. Animals were divided into ®ve groups (seven rats in each group) according to infused solution and epalrestat treatment, as follows: group S, 0´9% saline infusion; group G, 10% glucose infusion; group EG, 10% glucose infusion and epalrestat pre-treatment; group M, 10% mannitol infusion; group EM, 10% mannitol infusion and epalrestat pre-treatment. Each loading solution contained 1´0% inulin (Inutest, Lavosan-Gesellschaft mbH, Linz, Austria) for measurement of glomerular ®ltration rate (GFR). The osmolarity of 0´9% saline solution was 0´31 osm/ kg and that of 10% glucose or mannitol solution was 0´56 osm/kg.
Surgical preparation
Animals were anaesthetized with pentobarbital sodium (50 mg/kg body weight, i.p., Abbott Laboratories, North Chicago IL, USA) and placed on a warm plate to maintain their body temperature at 378C. Tracheostomy was done to facilitate respiration. The left carotid artery was cannulated (PE50, Becton Dickinson, Parsippany NJ, USA) for blood sampling and the left cervical vein was cannulated for infusion. With a small incision, another catheter was inserted into the bladder for urine sampling.
Infusion experimental protocols
Infusion was started immediately after surgery and continuedthroughoutthe experiment at a rate of 100 mL/min (Peristaltic pump-1, Pharmacia, Uppsala, Sweden). After an equilibrium period of 120 min, clearance studies were performed for three successive 60-min periods. The volume of urine was measured, and inulin concentration and enzyme activities were determined. At the midpoint of each clearance study (at 150, 210 and 270 min), 400 mL of blood was drawn from the carotid artery to determine plasma inulin concentration. The plasma glucose concentration was measured at the end of the infusion study.
Immediately after these clearance studies, both kidneys were removed and washed free of blood with ice-cold isotonic saline. Cortical tissue was separated and stored at 7808C until analysis.
Enzyme assays
Urine samples were dialysed against deionized water for 12 h before analysis. A Meiassay NAG-R kit (Meiji Seika, Tokyo, Japan) was used to determine NAG activity. 12 AAP activity was determined using L-alanine-3,5-dibromo-4hydroxyanilide (Asahi Kasei Kogyo, Tokyo, Japan) as a chromogenic substrate. 3 GGT activity was determined according to the modi-®ed method recommended by the Scandinavian Society of Clinical Chemistry. 13 DAPIV activity was determined using 7-glycylproline-4-methylcoumarin amide (Peptide Institute, Minoh, Japan) as a¯uorogenic substrate. 14
Determination of inulin concentration
Concentrations of plasma and urinary inulin were determined by the anthrone method. 15 As anthrone also reacts with glucose, we made a correction to each sample according to its glucose concentration.
Determination of sorbitol and glucose concentrations in renal cortical tissues
The renal cortex was minced with small scissors. The tissue was homogenized in three volumes (v/w) of cold perchloric acid (1 mol/L) with a homogenizer (Polytron Model PT 10/35, Kinematica AG, Switzerland) and deproteinized. The homogenate was centrifuged for 30 min at 17 000 g, the supernatant collected and its pH adjusted to 9´4 with 2 mol/L KOH. The supernatants were then ®ltered through 0´45 mm mesh (Dismic-25, Toyo Roshi Kaisha, Tokyo, Japan), and the protein-free ®ltrate was assayed for sorbitol and glucose contents.
Sorbitol concentration was measured by enzymatic assay with sorbitol dehydrogenase. 16 Glucose concentration was measured by the hexokinase/glucose-6-phosphate dehydrogenase method. 17
Statistical analysis
Results are expressed as means+standard error of the mean (SEM). Data were analysed using analysis of variance (ANOVA) or unpaired t-tests, as appropriate, with P50´05 considered statistically signi®cant. Table 1 shows the changes in GFR of each group during three consecutive periods of clearance study. There were no signi®cant differences in GFR between the groups studied throughout the experiment. Also, no signi®cant time-related changes were observed in any group of rats studied.
RESULTS
The urine volume of each group at 180 min (120±300 min) and the plasma glucose concentration at the end of the infusion study are shown in Table 2 . Compared with the salineinfused control group (group S), all the other groups showed signi®cant increases in urine volume (P50´01 in each group). Group EG (glucose infusion and epalrestat pre-treatment) and group EM (mannitol infusion and epalrestat pre-treatment) had signi®cantly higher urine volumes compared with that of group G (glucose infusion) (P50´001). There were no signi®cant differences in urine volume between group EM (mannitol infusion and epalrestat pre-treatment) and group M (mannitol infusion).
The plasma glucose concentration of groups G and EG were similar and signi®cantly higher than those of the other three groups (P50´001). Pre-treatment with epalrestat did not affect plasma glucose concentration. Figure 1 (a) shows urinary enzyme excretion with time. None of the four enzymes showed a distinct¯uctuation pattern over the three periods, although there was a slight tendency for GGT excretion to decrease over time. Figure 1(b) illustrates the cumulative urinary excretion of the enzymes over the entire 180-min period (120±300 min). In group G (glucoseloaded), urinary NAG, AAP, GGT and DAPIV excretion was signi®cantly higher compared with that in group S (P50´005, P50´05, P50´01, P50´01, respectively). This increase was prevented by epalrestat pre-treatment (group EG) (P50´005, P50´05, P50´005, respectively). Figure 2 shows the glucose and sorbitol concentrations of renal cortical tissue, measured at the end of the infusion studies. Regardless of epalrestat pre-treatment, renal cortical glucose concentration in the glucose-infused groups (groups G and EG) was signi®cantly higher compared with that in group S (P50´005 and P50´005, respectively). The glucose-infused groups (groups G and EG) also showed a signi®cant increase in cortical sorbitol concentration (see Fig. 2 , right panel), which was completely prevented by pre-treatment with epalrestat. The mannitol-infused groups (groups M and EM) showed no changes in cortical glucose or sorbitol concentrations compared with those in group S. Table 3 shows that the cumulative urinary excretion of enzymes over the entire 180-min period (120±300 min) was signi®cantly correlated with renal cortical sorbitol concentration in all the rats (n=35).
DISCUSSION
The primary goal of the present study was to determine the effects of renal sorbitol accumulation on urinary excretion of enzymes and to assess whether this could be prevented by administration of a speci®c aldose reductase inhibitor.
Plasma glucose concentration of glucoseinfused rats was signi®cantly higher compared with other groups (see Table 2 ). However, the transient hyperglycaemia did not have any sig-ni®cant effect on GFR during the infusion period (see Table 1 ). This enabled us to study the effects of hyperglycaemia on renal tubular function without alteration in glomerular function. In the glucose-infused group (group G), urinary NAG, AAP, GGT and DAPIV excretion was signi®cantly greater compared with the control group (see Fig. 1 ). Despite the fact that the osmolarity of the mannitol solution was similar to that of the glucose solution ( 0´56 osm/kg), urinary enzyme excretion did not signi®cantly change in the mannitol group (group M). Therefore, it is unlikely that the changes in enzyme excretion were related to osmotic diuresis and/or osmotic impact on renal tubular cells.
In the glucose-infused groups (groups G and EG), renal cortical glucose concentration was signi®cantly higher compared with the other groups (see Fig. 2 ). The renal cortical glucose concentrations in the glucose-infused groups with and without epalrestat pre-treatment were not signi®cantly different, indicating that glucose reabsorption in the renal proximal tubules was not affected by epalrestat pre-treatment. However, the increase in renal cortical sorbitol concentration caused by glucose infusion was completely abolished by epalrestat pre-treatment. Thus, intracellular sorbitol accumulation in the renal cortex was effectively prevented by aldose reductase inhibition by epalrestat. At the same time, abnormal enzymuria observed in the glucose-loaded group was blocked either completely (NAG, AAP, GGT) or partially (DAPIV) by epalrestat pre-treatment. The concentration of cortical sorbitol correlated with urinary enzyme excretion (see Table 3 ). Therefore, we conclude that the increased urinary enzyme excretion observed during glucose infusion was not caused by hyperglycaemia and/or glucosuria per se but was most likely to be due to facilitated intracellular accumulation of sorbitol as a result of activation of the polyol pathway.
Aldose reductase is widely expressed in mammalian tissues. 11 Hexokinase, involved in the glycolytic pathway, is also present in a wide range of mammalian tissues. Aldose reductase has a low af®nity (high Km value) for its substrate, glucose, compared with hexokinase. Under normal conditions, the sorbitol pathway accounts for only 3% of glucose metabolism. 16 However, this activity increases by two to fourfold in a concentration-dependent manner as the ambient glucose concentration rises above physiolo-gical levels. 16, 18 As sorbitol penetrates biological membranes only poorly, it tends to accumulate within the cells and leads to osmotic swelling. Thus, we suggest that increased glucose reabsorption increases polyol pathway activity, which leads to sorbitol accumulation and 396 Ishii et al. osmotically induced tissue damage. It is possible that this tissue damage is manifested as excretion of urinary enzymes. At present, several possible mechanisms have been suggested for the development of diabetic complications via the activated polyol pathway. These include: (1) osmotic swelling by sorbitol accumulation; (2) altered myo-inositol metabolism; (3) pseudohypoxia theory, due to changed redox state; (4) accumulation of type IV collagen and ®bronectin; (5) advanced protein glycation; and (6) oxidative stress. 19±28 In addition, recent studies have also shown that an activated protein kinase C (PKC)-dependent pathway in proximal tubular cells is associated with hyperglycaemia-induced cell injury. 24, 29 Therefore, hyperglycaemia may simultaneously activate two intracellular pathways, such as the polyol pathway and a PKC-dependent activation pathway. However, none of these possible mechanisms has yet been con®rmed.
The proximal tubules are the most metabolically active and damage-sensitive regions. As reabsorption and concentration of glucose takes place in proximal tubules it is the most susceptible region to hyperglycaemia. There is good experimental evidence that the blockade of renal proximal tubular transport of glucose by phloridzin prevents intracellular sorbitol accumulation, urinary enzyme leakage and apoptosis in renal proximal tubular cells in hyperglycaemic rats. 6, 30 Thus, available evidence strongly supports the view that the polyol pathway is associated with abnormal enzymuria and development of diabetic nephropathy.
These results suggested that abnormal enzymuria is induced by the following mechanisms in hyperglycaemia: (1) facilitated reabsorption and accumulation of glucose in proximal tubular cells; (2) increased polyol pathway activity; (3) a cluster of pathophysiologic phenomena induced by the activated polyol pathway, such as osmotic swelling of the cells and changed redox state; and (4) proximal tubular cell damage and abnormal urinary enzyme excretion. Aldose reductase inhibitors may be useful to prevent this sequence of events.
It is possible that a deranged polyol pathway is not the sole pathogenetic factor for abnormal enzyme excretion. It would be of interest to study the role of the other hyperglycaemiainduced derangements, such as PKC-dependent pathway. Hyperglycaemia provokes multiple abnormalities including derangement of the polyol pathway, and these, together or sepa-rately, initiate renal cell damage. Although each system may play a signi®cant role, our data emphasize the importance of deranged polyol pathway activity in the pathogenesis of abnormal urinary enzyme excretion.
